Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

Phase 2RecruitingNCT06537843

Hospital Municipal São José100 enrolled

Overview

Phase 2 clinical trial to evaluate the combination of venetoclax, cytarabine and metformin in relapsed-refractory and induction ineligible acute myeloid leukemia.

Subjects will be included voluntarily after informed consent. Diagnosis of AML in accordance with the WHO classification and determination of inegibility to induction therapy or refractory or relapsed disease after initial treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Acute Myeloid Leukemia

Interventions

VenetoclaxDRUG

Venetoclax, PO (tablet), 200 - 400mg, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).

Cytarabine InjectionDRUG

Cytarabine, Subcutaneous injection, 10 - 100mg per square meter, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).

MetforminDRUG

Metformin, PO (tablet), 850mg, three times a day, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of AML in accordance with the World Health Organization criteria. * Ineligibility for induction chemotherapy due to age (≥ 70 years) or, for patients 18 to 74 years of age, ECOG-PS 2 or 3, creatinine clearance below 60 mL/min/1,73m², left ventricular ejection fraction ≤ 50%. * Projected life expectancy of at least 12 weeks. * Not requiring supplemental oxygen or substitutive renal therapy. * Female participants must be either postmenopausal, surgically sterile or practicing at least one protocol specified method of birth control starting at Study Day 1 through at least 180 days after the last dose of study drug. * Male participants must agree, from Study Day 1 through at least 180 days after the last dose of study drug, to practice protocol specified methods of contraception and to refrain from sperm donation from initial study drug administration through at least 180 days after the last dose of study drug. * Participant must voluntarily sign and date an informed consent form, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures. Exclusion Criteria: * Diagnosis of acute promyelocytic leukemia (APL). * Known central nervous system (CNS) involvement with AML. * Known human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection, or other active viral, bacterial or fungal infection requiring treatment. * History of other malignancies prior to study entry, with the exception of non-melanoma skin cancer. * Chronic Liver Disease and Cirrhosis with a class B or C Child-Pugh score.

Locations (5)

Hospital Ophir Loyola

Belém, Brazil

NOT_YET_RECRUITING

Hospital de Clínicas da UFPR

Curitiba, Brazil

NOT_YET_RECRUITING

Hospital Universitario Polydoro Ernani de Sao Thiago

Florianópolis, Brazil

NOT_YET_RECRUITING

Outcomes

Primary Outcomes

Overall Survival (OS)

Overall survival is defined as the time from patient inclusion to the date of death, using Kaplan-Meier methodology.

Time frame: 12 months and 24 months

Secondary Outcomes

Composite Complete Response Rate (CCR)

Percentage of participants with complete remission (CR) or complete remission with partial (CRh) or incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on physical examination, bone marrow results and hematology values according to the revised guidelines by the 2022 European LeukemiaNet AML Diagnosis and Treatment Recommendations.

Time frame: 12 months and 24 months

Negative Measurable Residual Disease (MRD) Rate

Percentage of participants with CR, CRh or CRi with negative measurable residual disease (MRD) as assessed by the investigator, in accordance with ELN recommendations, defined as having less than 10-³ residual blasts per leukocyte measured in the bone marrow.

Time frame: 12 months and 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.